Questions about this technology? Ask a Technology Manager
Download Printable PDF
North Carolina State University is seeking commercial partners to license and commercialize a novel cancer immunotherapeutic delivery system of anti-PD-L1.Abstract
Cancer immunotherapy research is a rapidly emerging field. Over half of current cancer clinical trials include formats of immunotherapy, the area has seen remarkable results. The first anti-PD-L1 inhibitor has recently and rapidly been approved by the FDA. For a productive immune response a number of immunological checkpoints must be past, to guard against unwanted or harmful self-directed activities, this may act as a barrier to successful immunotherapies. By blocking the inhibitory checkpoints, antitumor activity may be generated, however these checkpoint blockade therapy have limited therapeutic benefits in many patients, with grade ¾ adverse effects occurring. How to enhance these therapies have become a focus in the field.
Researchers at North Carolina State University have developed a novel delivery system for the promoted delivery of anti-PD-L1 (aPDL1) to eradicate residual tumor cells, using in-situ activation of platelets. Reoccurrence of cancer after a surgical resection remains a significant challenge in cancer management. This is due to residual microtumors in the surgical bed and circulating tumor cells (CTCs). The intrinsic wound and CTCs tropic properties of platelets, can target microtumors at the surgical wound and the CTCs in blood vessels. This has been tested with melanoma and breast-cancer murine models. This successful model overcomes the limitations of anti-PD therapy. The pro-inflammatory environments created by platelets could upregulate PDL1 expression of tumor and boost T cell activity. This new methodology for triggered release of agent, activation by PMP generation, which facilitates aPDL1 binding to tumor and APC cells. This programmed combination delivery strategy may inspire new treatments that involve localized and bio-responsive release of other therapies.Advantages